Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

Nat Rev Cancer. 2005 Apr;5(4):297-309. doi: 10.1038/nrc1588.


The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy. One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-kappaB (NF-kappaB), which regulates cell survival. NF-kappaB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance. What evidence is there that inhibitors of NF-kappaB might promote apoptosis in cancer cells and can NF-kappaB inhibitors be used to overcome resistance to chemotherapeutic agents?

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Diet
  • Drug Resistance, Neoplasm*
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Models, Biological
  • NF-kappa B / antagonists & inhibitors*
  • NF-kappa B / genetics
  • Proteome / antagonists & inhibitors
  • Steroids / pharmacology


  • Anti-Inflammatory Agents, Non-Steroidal
  • Antineoplastic Agents
  • NF-kappa B
  • Proteome
  • Steroids